tiprankstipranks
Creo Medical Group PLC (GB:CREO)
LSE:CREO

Creo Medical (CREO) Share Price & Analysis

16 Followers

CREO Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range29.12p - 50.00p
Previous Close33p
Volume87.32K
Average Volume (3M)466.49K
Market Cap
£119.29M
Enterprise Value117.87M
Total Cash (Recent Filing)£13.10M
Total Debt (Recent Filing)£11.68M
Price to Earnings (P/E)
Beta0.57
Sep 26, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding361,476,442
10 Day Avg. Volume64,541
30 Day Avg. Volume466,486
Standard Deviation0.19
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.81
Price to Sales (P/S)4719.92
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
Price Target Upside142.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

4.54%0.37%0.00%95.09%
0.00% Other Institutional Investors
95.09% Public Companies and
Individual Investors

CREO FAQ

What was Creo Medical Group PLC’s price range in the past 12 months?
Creo Medical Group PLC lowest share price was 29.12p and its highest was 50.00p in the past 12 months.
    What is Creo Medical Group PLC’s market cap?
    Currently, no data Available
    When is Creo Medical Group PLC’s upcoming earnings report date?
    Creo Medical Group PLC’s upcoming earnings report date is Sep 26, 2024 which is in 70 days.
      How were Creo Medical Group PLC’s earnings last quarter?
      Creo Medical Group PLC released its earnings results on May 15, 2024. The company reported -0.026p earnings per share for the quarter, missing the consensus estimate of N/A by -0.026p.
        Is Creo Medical Group PLC overvalued?
        According to Wall Street analysts Creo Medical Group PLC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Creo Medical Group PLC pay dividends?
          Creo Medical Group PLC does not currently pay dividends.
          What is Creo Medical Group PLC’s EPS estimate?
          Creo Medical Group PLC’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Creo Medical Group PLC have?
          Creo Medical Group PLC has 361,476,440 shares outstanding.
            What happened to Creo Medical Group PLC’s price movement after its last earnings report?
            Creo Medical Group PLC reported an EPS of -0.026p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.877%.
              Which hedge fund is a major shareholder of Creo Medical Group PLC?
              Currently, no hedge funds are holding shares in GB:CREO
              ---

              Company Description

              Creo Medical Group PLC

              Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. Its reportable segments being the research and development of electrosurgical medical devices relating to the field of surgical endoscopy.
              ---

              CREO Stock 12 Month Forecast

              Average Price Target

              80.00p
              ▲(142.42% Upside)
              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"29p","42":"42p","55":"55p","68":"68p","81":"81p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">80.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">80.00p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">80.00p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,42,55,68,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Feb<br/>2024","9":"May<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.75,36.38461538461539,40.01923076923077,43.65384615384615,47.28846153846154,50.92307692307692,54.55769230769231,58.19230769230769,61.82692307692308,65.46153846153845,69.09615384615384,72.73076923076923,76.36538461538461,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.75,36.38461538461539,40.01923076923077,43.65384615384615,47.28846153846154,50.92307692307692,54.55769230769231,58.19230769230769,61.82692307692308,65.46153846153845,69.09615384615384,72.73076923076923,76.36538461538461,{"y":80,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.75,36.38461538461539,40.01923076923077,43.65384615384615,47.28846153846154,50.92307692307692,54.55769230769231,58.19230769230769,61.82692307692308,65.46153846153845,69.09615384615384,72.73076923076923,76.36538461538461,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.25,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.25,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.5,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.5,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.5,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.1,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":42.25,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":31,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":34.5,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35.75,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":35,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.5,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              EKF Diagnostics Holdings
              Tristel
              Genedrive
              Synairgen

              Best Analysts Covering CREO

              1 Year
              Paul CuddonDeutsche Numis
              1 Year Success Rate
              0/1 ratings generated profit
              0%
              1 Year Average Return
              -5.70%
              reiterated a buy rating 3 months ago
              Copying Paul Cuddon's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -5.70% per trade.
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis